Navigation Links
Hemodialysis Patient Share for Sanofi's Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
Date:4/15/2013

EXTON, Pa., April 15, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that in hemodialysis (HD), Sanofi's Ferrlecit patient share has experienced a significant 9 percent increase between Q4 2012 and Q1 2013. In Chronic Kidney Disease Non-Dialysis (CKD-ND), patient share for American Regent's Venofer has increased significantly since this period last year (at the expense of Ferrlecit and AMAG Pharmaceuticals' Feraheme), although the percent of patients on IV iron in this patient population is considerably lower than in the HD population.   

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

The TreatmentTrends®: Nephrology (U.S.) report, in which 200 U.S. based nephrologists were surveyed, also finds that—in regard to bone and mineral metabolism—reported phosphate binder use declined in every late stage CKD and dialysis patient population, significantly in HD and peritoneal dialysis, compared to Q4 2012. The report also notes a decline of phosphate binder use over longer time periods.

"There may be several reasons why phosphate binder use appears to be declining over time, including influence of dialysis bundling, cost containment pressures for the facility and more expensive patient co-pays," said BioTrends Research Group Director of Nephrology Rob Dubman . "Another theory is less use of combination binder therapy—in fact, while reported combination use has remained fairly consistent in CKD-ND, the TreatmentTrends Nephrology report series has found a significant decline of binder combination therapy in the dialysis population over time."

The first quarter of 2013 was also marked with clinical advances for Keryx Biopharmaceuticals' Zerenex, Rockwell Medical's SFP and Vifor Pharma's PA21. Despite these clinical advances, surveyed nephrologists' familiarity with these products is generally low, but interest is moderate to high after respondents reviewed a brief product description. The report provides further details regarding the percent of patients likely to be candidates for these products and likely products to be replaced by the new iron-based binders.

TreatmentTrends®: Nephrology (U.S.) is a syndicated quarterly report series, based on primary market research that provides a comprehensive view of the current and expected future management of renal anemia and bone and mineral metabolism in patients with chronic kidney disease. Topics include percent of patients on each therapy, patient share, therapy initiation levels, perception of current laboratory values, attribute importance and performance ratings, bundling, compliance, statement agreements, reaction to new products in development, among other topics. The Q1 2013 wave published in March 2013 and the Q2 2013 wave will publish in June 2013. Survey instrument is available upon request.

Webinar
Media members are welcome to attend our upcoming webinar entitled Renal Anemia in Chronic Kidney Disease (CKD): Following the Omontys Recall. This webinar will be held on April 25 at 10 AM EST and on April 30 at 2 PM EST. To learn more and to register, click here.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at www.bio-trends.com.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cantel Medicals Mar Cor Purification Subsidiary Acquires Hemodialysis Water Business from Siemens Water Technologies Business Unit
2. Home Hemodialysis Patients Urge Medicare to Fix HHD Training Reimbursement
3. NxStage Announces CE Mark Approval for Nocturnal Home Hemodialysis
4. NxStage Initiates 2013 Call to Action Campaign with Launch of Hemodialysis At Home: A Better Way For a Better Life
5. NxStage Home Hemodialysis Patient Awareness Tour Kicks Off January 29th
6. NxStage Submits Formal Comments to CMS to Improve Patient Access to Life-changing More Frequent Home Hemodialysis Therapy
7. Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis
8. FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with the NxStage System One
9. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
10. Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
11. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... BOCA RATON, Fla. , Jan. 19, 2017 ... ), a medical device company specializing in the ... conditions, such as keloids, with superficial radiation therapy, ... quarter and full year 2016 financial results on Thursday, ... The Company will hold a conference call ...
(Date:1/19/2017)... January 19, 2017 New ... to Address Motor Symptoms and Motor Complications in ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) C ... European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
(Date:1/19/2017)... -- The Global Therapy Partnering Terms and Agreements since ... and agreements entered into by the world,s leading healthcare ... deals by value - Deals listed by company A-Z, ... report provides understanding and access to the partnering deals ... companies. The report provides an analysis of partnering ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Journey to Christmas:” a beautiful and enchanting ... of published author, Kimberly Cordoves, a mother of three in Oklahoma City, and a devoted ... idea of writing a book has been in the back of my mind for years, ...
(Date:1/20/2017)... ... 2017 , ... “The Land of More and More”: a brilliant story ... and shares the simple and achievable answer. “The Land of More and More” is ... Missionary Church in Angola, Indiana where he works with the children’s ministry department. ...
(Date:1/19/2017)... ... ... Today, the Centers for Medicare & Medicaid Services (CMS) announced over 359,000 clinicians ... 2017. Clinicians who participate in APMs are paid for the quality of care they ... to build a system that delivers better care and one in which clinicians work ...
(Date:1/19/2017)... ... January 19, 2017 , ... Next week after January 20th, the fear ... political games that circumvent health needs of over 30 million. Many interviews with Dr. ... and needs government public servants were suppose to prioritize. Interviews provided below. ...
(Date:1/19/2017)... ... 19, 2017 , ... With the cold weather here, many people will have to clear snow ... clearing large amounts of snow, but they can be dangerous when used incorrectly. That’s why ... Commission for the proper use of snow blowers:, , When removing ...
Breaking Medicine News(10 mins):